Peripheral Arterial Disease (PAD) Pipeline Research Report 2024: Comprehensive Insights About 22+ Pipeline Drugs Featuring AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa, IsomAb
November 21, 2024 04:20 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. "Peripheral Arterial...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
October 22, 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
October 01, 2024 07:00 ET
|
CytoSorbents
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
August 07, 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
May 02, 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
XARELTO Market Size, Forecast, and Market Insight to 2032, with Focus on the United States and Japan
April 04, 2024 11:13 ET
|
Research and Markets
Dublin, April 04, 2024 (GLOBE NEWSWIRE) -- The "XARELTO Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.The report provides...
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
December 28, 2023 07:00 ET
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
September 27, 2023 07:00 ET
|
CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
September 01, 2023 16:43 ET
|
CytoSorbents
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
July 07, 2023 07:07 ET
|
CytoSorbents
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...